News | June 14, 2026
Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
Samelisant will be the centerpiece of Suven’s scientific presence
Samelisant will be the centerpiece of Suven’s scientific presence
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
The decision was driven by results from the Phase III CAPItello-281 trial,
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards
The regulatory decision follows promising results from RIVER-81
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Two-year collaboration aims to strengthen primary healthcare systems, generate real-world evidence, and support responsible adoption of AI and digital health technologies across South-East Asia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
